These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36753444)

  • 1. Protease-Responsive Potential-Tunable AIEgens for Cell Selective Imaging of TMPRSS2 and Accurate Inhibitor Screening.
    Cheng Y; Clark AE; Yim W; Borum RM; Chang YC; Jin Z; He T; Carlin AF; Jokerst JV
    Anal Chem; 2023 Feb; 95(7):3789-3798. PubMed ID: 36753444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease-Responsive Peptide-Conjugated Mitochondrial-Targeting AIEgens for Selective Imaging and Inhibition of SARS-CoV-2-Infected Cells.
    Cheng Y; Clark AE; Zhou J; He T; Li Y; Borum RM; Creyer MN; Xu M; Jin Z; Zhou J; Yim W; Wu Z; Fajtová P; O'Donoghue AJ; Carlin AF; Jokerst JV
    ACS Nano; 2022 Aug; 16(8):12305-12317. PubMed ID: 35878004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Transmembrane Protease Serine 2 (TMPRSS2) Non-Protease Domains Regulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike-Mediated Virus Entry.
    Strobelt R; Adler J; Shaul Y
    Viruses; 2023 Oct; 15(10):. PubMed ID: 37896901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure and activity of human TMPRSS2 protease implicated in SARS-CoV-2 activation.
    Fraser BJ; Beldar S; Seitova A; Hutchinson A; Mannar D; Li Y; Kwon D; Tan R; Wilson RP; Leopold K; Subramaniam S; Halabelian L; Arrowsmith CH; Bénard F
    Nat Chem Biol; 2022 Sep; 18(9):963-971. PubMed ID: 35676539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges.
    Mahmoud IS; Jarrar YB
    Mol Biol Rep; 2021 May; 48(5):4667-4675. PubMed ID: 34023987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of SARS-CoV-2 Spike Mutations on Its Activation by TMPRSS2 and the Alternative TMPRSS13 Protease.
    Stevaert A; Van Berwaer R; Mestdagh C; Vandeput J; Vanstreels E; Raeymaekers V; Laporte M; Naesens L
    mBio; 2022 Aug; 13(4):e0137622. PubMed ID: 35913162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metalloproteinase-Dependent and TMPRSS2-Independent Cell Surface Entry Pathway of SARS-CoV-2 Requires the Furin Cleavage Site and the S2 Domain of Spike Protein.
    Yamamoto M; Gohda J; Kobayashi A; Tomita K; Hirayama Y; Koshikawa N; Seiki M; Semba K; Akiyama T; Kawaguchi Y; Inoue JI
    mBio; 2022 Aug; 13(4):e0051922. PubMed ID: 35708281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
    Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
    J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
    Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
    J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation.
    Hörnich BF; Großkopf AK; Schlagowski S; Tenbusch M; Kleine-Weber H; Neipel F; Stahl-Hennig C; Hahn AS
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33608407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactive Centre Loop Mutagenesis of SerpinB3 to Target TMPRSS2 and Furin: Inhibition of SARS-CoV-2 Cell Entry and Replication.
    Singh S; O'Reilly S; Gewaid H; Bowie AG; Gautier V; Worrall DM
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformational response to ligand binding of TMPRSS2, a protease involved in SARS-CoV-2 infection: Insights through computational modeling.
    Frumenzio G; Chandramouli B; Besker N; Grottesi A; Talarico C; Frigerio F; Emerson A; Musiani F
    Proteins; 2023 Sep; 91(9):1288-1297. PubMed ID: 37409524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells.
    Mahoney M; Damalanka VC; Tartell MA; Chung DH; Lourenço AL; Pwee D; Mayer Bridwell AE; Hoffmann M; Voss J; Karmakar P; Azouz NP; Klingler AM; Rothlauf PW; Thompson CE; Lee M; Klampfer L; Stallings CL; Rothenberg ME; Pöhlmann S; Whelan SPJ; O'Donoghue AJ; Craik CS; Janetka JW
    Proc Natl Acad Sci U S A; 2021 Oct; 118(43):. PubMed ID: 34635581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19.
    Mantzourani C; Vasilakaki S; Gerogianni VE; Kokotos G
    Expert Opin Drug Discov; 2022 Mar; 17(3):231-246. PubMed ID: 35072549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BC-11 is a covalent TMPRSS2 fragment inhibitor that impedes SARS-CoV-2 host cell entry.
    Moumbock AFA; Tran HTT; Lamy E; Günther S
    Arch Pharm (Weinheim); 2023 Jan; 356(1):e2200371. PubMed ID: 36316225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Inhibition of Vacuolar-ATPase and TMPRSS2 Is Required for Complete Blockade of SARS-CoV-2 Entry into Cells.
    Icho S; Rujas E; Muthuraman K; Tam J; Liang H; Landreth S; Liao M; Falzarano D; Julien JP; Melnyk RA
    Antimicrob Agents Chemother; 2022 Jul; 66(7):e0043922. PubMed ID: 35703551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
    Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
    Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving Soluble Expression of SARS-CoV-2 Spike Priming Protease TMPRSS2 with an Artificial Fusing Protein.
    Ye X; Ling X; Wu M; Bai G; Yuan M; Rao L
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene of the month:
    Thunders M; Delahunt B
    J Clin Pathol; 2020 Dec; 73(12):773-776. PubMed ID: 32873700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.